A Phase 2 interventional study of Daratumumab and Cyclophosphamide in Amyloidosis, sponsored by Janssen Research & Development, LLC. Active, not recruiting at 46 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.
Among the 141 studies in Amyloidosis with a site in United States, this one is the 28th largest by enrollment of the 99 interventional ones that give a count, is one of 5 that started in 2022, is one of 30 in phase 2, reaches primary completion later than 3 of the 46 other live ones, and was the 100th registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
GlaxoSmithKline · Sites in United States, Australia, United Kingdom
Ages 18+
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Germany, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 46 · Phase 3 31 · Phase 4 3
First in 1979; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 151 is above the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 45 across the 99 interventional studies, 107 across the 41 observational. Of the 84 that completed or were terminated, 44 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 141 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 3 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Amyloidosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT06097832Nexcella Inc.Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | 2026-12 |
| NCT05951816University of Tennessee Graduate School of MedicineA Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | 2026-12 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 141 studies in Amyloidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to characterize cardiac safety of Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCd) treatment regimens (Arm A: daratumumab + immediate VCd treatment and Arm B: daratumumab + deferred VCd) in newly diagnosed systemic amyloid light chain (AL) amyloidosis with cardiac involvement and to identify potential mitigation strategies for cardiac toxicity (cohort 1); to characterize the pharmacokinetics of subcutaneous (SC) daratumumab, among racial and ethnic minorities, including Black or African American, with newly diagnosed AL amyloidosis treated with D-VCd (cohort 2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Difference between iFLC and uninvolved FLC (dFLC) >= 40mg/L per central laboratory Serum involved free light chain (iFLC) >= 40 mg/L with an abnormal kappa:lambda ratio Serum M-protein >= 0.5 g/dL
Exclusion Criteria:
Participant received any of the following therapies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with newly diagnosed systemic amyloid light chain (AL) amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive daratumumab 1800 milligrams (mg) subcutaneously (SC) starting on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone
Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (Cyclophosphamide 300 mg/m\^2 either orally or IV, Bortezomib 1.3 mg/m\^2 SC or IV, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).
Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone
Participants with racial and ethnic minorities, including Black or African American participants, with newly diagnosed AL amyloidosis will receive SC injection of daratumumab 1800 mg SC on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (cyclophosphamide 300 milligrams per meter square \[mg/m\^2\] either orally or intravenously \[IV\], bortezomib 1.3 mg/m\^2 SC or IV, dexamethasone 40 mg weekly either orally or IV) weekly starting at Cycle 1 Day 1 up to Day 22 in every 28-day cycle for a maximum of 6 cycles (Cycle 6 Day 22).
Drug: Daratumumab · Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone
Daratumumab will be administered subcutaneously.
Also known as: JNJ-54767414
Cyclophosphamide will be administered either orally or IV.
Bortezomib will be administered by SC injection or IV.
Dexamethasone will be administered orally or IV.
Number of Participants with Cardiac Events of Any Toxicity Grade
Number of participants with cardiac events of any toxicity grade will be reported.
Time frame: Up to 12 months
Observed Concentration Immediately Prior to the Next Study Treatment Administration (Ctrough) of Daratumumab
Ctrough is defined as the observed concentration immediately prior to the next study treatment administration.
Time frame: Cycle 3 Day 1 predose (each cycle is of 28 days)
Overall Complete Hematologic Response (HemCR) Rate
Overall HemCR rate is defined as percentage of participants who achieve HemCR during or after the study treatment.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
HemCR Rate
HemCR rate at 6 month is defined as percentage of participants who achieve HemCR at 6 month during or after the study treatment.
Time frame: At 6 months
Very Good Partial Response (VGPR) or Better Rate
Hematologic greater than or equal to (\>=) VGPR rate is defined as percentage of participants who achieve hematologic response of VGPR or better.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Time to HemCR or (VGPR or Better)
For participants who achieve HemCR (or \>=VGPR), time to HemCR (or \>=VGPR) is defined as the time between the date of first study treatment and the first efficacy evaluation at which the participant has met all criteria for hematologic complete response (CR) (or \>=VGPR).
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Duration of Response (HemCR and VGPR or Better)
For participants who achieve HemCR (or \>=VGPR), duration of HemCR (or \>=VGPR) is defined as the time between the date of initial documentation of HemCR (or \>=VGPR) to the date of first documented evidence of hematologic progressive disease or death, whichever comes first.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Organ Response Rate (OrRR)
Organ response rate is defined as the percentage of participants who achieve organ response in each corresponding organ (kidney, heart, liver).
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Overall Survival (OS)
OS is measured from the date of first study treatment to the date of the participant's death.
Time frame: Until Cycle 12 or Month 12 (whichever occurs later)
Time to Subsequent Therapy
Time to subsequent therapy for amyloid light chain (AL) amyloidosis is defined as the time from the date of first study treatment to the start date of subsequent AL amyloidosis (non-protocol) treatment.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Number of Participants with Adverse Events (AEs) by Severity
Number of participants with AEs by severity will be reported. An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Serum Concentration of Daratumumab
Serum samples will be analyzed to determine concentrations of daratumumab.
Time frame: Up to 3 years
Number of Participants with Antibodies to Daratumumab
Number of participants with antibodies to daratumumab will be reported.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Number of Participants with Antibodies to Recombinant Human Hyaluronidase PH20 Enzyme (rHuPH20)
Number of participants with antibodies to rHuPH20 will be reported.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Change from Baseline in Clinical Signs and Symptoms Score of Cardiac AL Amyloidosis
Change from baseline in clinical signs and symptoms score of cardiac AL amyloidosis will be reported.
Time frame: Up to Cycle 12 or Month 12 (whichever occurs later)
Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Data sharing details ↗ · www.janssen.com
No publications or documents are linked to this record.
Ran from Mar 2022 to primary completion in Feb 2026, 47 months.
Of 24 phase 2 interventional studies under Amyloidosis, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 64. This study's 47 months is close to that.
Completion moved twice since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, last on Nov 3, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →